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Summary
An immunotoxin has been made by coupling anti-human immunodeficiency virus (HIV) envelope
antibody 907 to ricinA chain (907-RAC). 907 recognizes an epitope within the immunodominant
PB-1 loop of gp120. Variant cells were selected by cloning persistently infected H9/human T
lymphocyte virus IIIB cells in the presence of the immunotoxin. Clones resistant to 907-RAC
arose at a frequency of 0.1-1.0%. Seven clones were selected for intensive analysis. When studied,
these clones fell into two distinct groups, members ofwhich appeared to be identical, suggesting
that the variation arose before the selection process. In contrast to the parent cells, none of the
cloned variants produced infectious HIV The first set of clones, designated the "E" variants,
expressed decreased levels ofthe HIV envelope on the cell surface. However, levels of intracellular
HIV antigens and reverse transcriptase were equal to or greater than that of the parental cell
line. Radioimmunoprecipitation demonstrated that the gp160 was truncated to 145 kD (gp120
was normal length), capable of binding to CD4, and, unlike normal gp160, was released in its
unprocessed form into the cellular supernatant. Sequence analysis demonstrated that a deletion
at codon 687 of the envelope gene resulted in the production of this truncated protein. Ultrastructural
analysis of E variants demonstrated some budding forms of virus, but also large numbers of
HIV within intracellular vesicles. The second set of variants, the "F" series, produced no HIV
antigens, reverse transcriptase, nor was there ultrastructural evidence of virus. However, proviral
DNA was present. Virus could not be induced with agents known to activate latent HIV These
cells also lacked cell surface CD4 and could not be infected with HIV These studies demonstrate
that variation in HIV can affect the phenotype of the cells carrying the altered virus, allowing
for escape from immunologic destruction. The E variants may serve as prototypes for attenuated
HIV, which could be used as a vaccine. We have reconstructed the mutation found in the E
variants within the infectious HIV clone HXB-2 and demonstrated that the resulting virus retains
its noninfectious phenotype.
W
e have previously coupled ricin A chain (RAC)t to mAb
907, which recognizes an epitope within the im-
munodominant PB-11oop of the HIV envelope protein. This
immunotoxin can effectively and specifically kill cellsinfected
with HIV (1). Antigenic variation can allow targets to avoid
immunologic destruction in both neoplastic and infectious
processes (2, 3). To study this phenomenon in HIVinfected
cells, we used 907-RAC to select for cells that escape the
action of the immunotoxin. Because the epitope recognized
'Abbreviations used in this paper. HTLV human T lymphocyte virus;
IC, infectious center; RAC, ricin A chain; SIV, simian immunodefi-
ciency virus.
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by antibody 907 lies within a hypervariable region ofthe HIV
envelope, we expected that variant cells surviving treatment
with the immunotoxin would have alterations in the struc-
ture of the epitope. Rather, we found that variation elsewhere
in the virus decreased or eliminated cell surface expression
of the epitope recognizedby 907. The studyofthese variants
has revealed information regarding processing and function
of the HIV envelope protein, as well as revealing mechanisms
of HIV variation.
Materials and Methods
Reagents, Viruses, andCells.
￿
Antibody 907 and the immunotoxin
907-RAC have been described elsewhere (1, 4). 907 binds to an
The Journal of Experimental Medicine " Volume 172
￿
September 1990
￿
745-757epitope within the hypervariable PB-1 loop of gp120 and reacts
only with the humanT lymphocyte virus(HTLV)-IIIB/LAV iso-
late ofHIV . The isotype-matched control antibody T7 is directed
against the synthetic polypeptide antigen (Tyr,Glu)-Ala-Lys (5) .
OKT4awaspurchased from OrthoDiagnostic Systems, Inc. (West-
wood, MA). Polyclonal anti-HIV antibodies were present in the
pooled serum from AIDS patients . Peroxidase-conjugated goat
anti-human Ig and fluorescein-conjugated goat anti-mouse Ig were
obtained from OrganonTeknika (Malvern, PA) . SolubleCD4was
obtained from Genentech (South San Francisco, CA) andwasim-
mobilizedon cyanogenbromide-activated sepharose (Pharmacia Fine
Chemicals, Piscataway, NJ) . TheH9 cells chronically infected with
the HIV isolateHTLVIIIB used in these studies were from E.-M .
Fenyo of the Karolinska Institute, Stockholm, Sweden . The cells
had been maintained in continuous culture for >1 yr before the
time of selectionwith theimmunotoxin.The infectiousHIVclone
HXB-2 hasbeen described elsewhere (6) . MalcolmMartin (NIH,
Bethesda, MD) provided the infectious clone NL4-3 as well as the
clinical isolate NY-5 (7) . HT4-6C cells are HeLa cells that have
been transfected with the gene encoding CD4. These cells stably
expressCD4on the cell surface (4). A3.01 cells, permissive for HIV
infection, were obtained from Tom Folks (8 ; Center for Disease
Control, Atlanta, GA). Cells were maintained in RPMI 1640
medium containing 10% FCS, penicillin, gentamicin, and 2-ME
(5 x 10- ' M) .
Selection of Immunotoxin-Resistant Cells.
￿
Bulk selections were
performedby incubating 2 x 105 H9/HTLVIIIB cells in 2 ml of
medium containing 907-RAC at 2.5 or 10 Rg/ml . The cells were
cultured for 10 d, with fresh immunotoxin being added on days
4and 8. Cloned variant cells were obtained by culturing 10-1,000
H9/HTLVIIIB cells per0.2 ml well in 96-well flat-bottomed tissue
culture trays. Cells were cloned in the presence of907-RAC at 2.5
Wg/ml . Fresh immunotoxin was, added every4 d for the first 3wk
of culture.
Focal Immunoassayfor the Detection ofHIVsecreting Cells.
￿
A focal
immunoassaywasused to quantify the number ofcells producing
infectious HIV (1, 4) . Cells to be tested were plated at different
concentrations on amonolayer of adherentHT4-6C cells in 6-well,
35-mm tissue culture plates (Falcon 3046; Becton Dickinson& Co .,
Mountain View, CA) . The test cells were washed off 24 h later,
andthemonolayerwas incubated for an additional 72 h . The HT4-
6C cells were then fixed in methanol and stained with human anti-
HIV serum followed by peroxidase-conjugated goat anti-human
Ig . The substrate, aminoethyl carbazole (Sigma ChemicalCo., St .
Louis, MO), produces a red precipitate in the presence of peroxi-
dase . Viral foci were identified by the presence ofstaining andmul-
tinucleated cells . The data are presented as the percentage of input
cells forming foci (infectious centers [ICs]) .
'SS-Methionine Incorporation .
￿
Protein synthesis in the presence
of the immunotoxin was measured as the incorporation of 35S-
methionine into cellular protein. Target cells (5 x 10°) were
plated, in triplicate, in flat-bottomed 96-well tissue culture plates
in 100 Fd of medium . An additional 100 p,l of medium containing
the immunotoxin or antibody 907 was added, and the cells were
cultured for72 h . Forthe final 16 hof the culture, s5S-methionine
wasadded to the cells (0.5 P,Ci/well in 20 Al) . Cells were harvested
onto glass filters using an automated cell harvester and washing
with methanol . The filters were then placed in 2 ml of scintillation
fluidandcounted in a scintillation counter (LS8000 ; Beckman In-
struments, Inc ., Fullerton, CA) . Results are shown as means and
SEM of triplicate samples .
Immunologic Detection ofHIVAntigens.
￿
Cell surface antigens
were detected using flow cytometry. Living cells were stained with
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mAb 907, OKT4a, or T7, followed by fluorescein-conjugated goat
anti-mouse Ig. Cells were then fixed in 2% paraformaldehyde and
analyzed by one-color flow cytometryon a FACstar (Becton Dick-
inson& Co .) . 5,000 cellswere analyzed. Results are plotted with
the cell number on the vertical axis and the log fluorescence inten-
sity on the horizontal axis. Intracellular antigens were detected on
cells that had first been fixed with methanol . The cells were then
stained withhuman anti-HIV serum, peroxidase-conjugated goat
anti-human Ig, and aminoethyl carbazole. The intracellular level
ofHIV p24 antigen was determined using the RetroTek p24 an-
tigen capture ELISA (Cellular Products, Buffalo, NY) . Cells were
washed in PBS and then lysed with 1% Triton X-100 . Serial dilu-
tions of the cell lysate were incubated on plates coated with anti-
p24mAbs. The plates were washed andincubatedwith biotinylated
humananti-HIV serum, followed by streptavidin-horse radish per-
oxidase, and then the peroxidase substrate tetramethylbenzidine .
Antigen levels were determined by comparison with standards
provided by the manufacturer.
Assayfor Supernatant Reverse Transcriptase.
￿
Reverse transcriptase
activity was measured in cell supernatants (9) by adding 10 U1 of
the supernatant to 20 ul of the following mixture : 50 mM Tris
HCI, pH 7.9, 75 mM KCI, 2 mM dithiothreitol, 5 MM MgCl2 ,
0.05% NP-40, 5 Ftg/ml poly(rA), 2.5 p.g/ml oligo(dT), and 20
PCi/ml 31P-dTTP. The supernatant and the mixture were in-
cubated for 2 h at 37°C, spotted onto DEAE paper, washed ex-
haustively in 2x SSC, and then once in 95% ethanol . Autoradio-
grams were then performed .
Electron Microscopy.
￿
Cells were fixed for 1 h at room tempera-
ture in 2.5% glutaraldehyde, 2.0% paraformaldehyde, 0.05%
trinitrocresol (Kodak, Rochester, NY), 0.1M tricine, 0.1% phos-
photungstic acid, 1.0% NaCl,0.1M Na cacodylate, pH 7 .2 . The
cells were washed twice in 0.1MNa cacodylate, pH 7.9, andthen
incubated for 1 h in 2.0% OSO4 and 0.8% K3Fe(CN)s in 0.1 M
Na cacodylate . Cellswere washed twiceand then treated with0.1%
tannic acid for 5 min and washed twice in tap water . The cells
dvere stained for 30 min with 1.0% aqueous uranyl acetate, pH
3.9, andthen dehydrated by successive exposure to 30, 60, 90, and
100% acetone . The dehydrated cells were incubated twice in low
viscosity Spurr's resin (Polysciences, Inc., Warrington, PA) . The
cells were then placed in Beem capsules (003 ; Polysciences, Inc.)
in fresh Spurr's and polymerized for 16 h at 70°C. Sections were
placed on 300-mesh copper grids and examined in an electron mi-
croscope (HU-11E-1; Hitachi, Tokyo, Japan) at 75 KV .
Radioimmunoprecipitation .
￿
Cells were incubated in methionine
and cysteine-free medium containing 10% dialyzed FCS and 35S-
cysteine and methionine (1,200 Ci/mM) to a final concentration
of 100 ACi/ml . After an incubation time of 12 h, medium was
removed, and the supernatants were spun at 2,000g for 10 min
to remove cells and debris . The supernatants were precleared by
incubation with normal rabbit serum and protein A-Sepharose
beads. Precipitation with antibody was performed by incubating
the supernatants with anti-HIV antisera and protein A-Sepharose
(Pharmacia Fine Chemicals) . Precipitation of CD4 binding pro-
teins wasperformed with rCD4 immobilized on cyanogen bromide-
activated sepharose. After 16 h ofincubation, immunoprecipitates
were collectedby centrifugation, washed repeatedly, resuspended
in SDS-PAGE sample buffer, heated for 3 min at 100°C, and ana-
lyzed by SDS-PAGE .
Genetic Analyses .
￿
Cellular DNA was prepared by incubating
10' cells in buffer containing 50 mM Tris, pH 8, 100mM EDTA
in the presence of 0.5% SDS and 500 14g/ml of proteinaseK for
16 h at 56°C with agitation . The resultingmixture was then ex-
tracted with phenol, phenol/chloroform, and then chloroform . TheDNA wasprecipitated from the aqueous phasewith ethanol. The
DNA was spooledonto a hooked pasteurpipette andresuspended
in Tris/EDTA buffer. DNA hybridization was performed using a
modification of the original method of Southern (10). DNA was
blotted onto nitrocellulose paper and then hybridized with either
the cloned HIV HXB-2 (6), which had been labeled with 32P
using random primers (Pharmacia Fine Chemicals), or with the
oligonucleotide 5'-dCCTATCTGTCCCCTCAGCTA (referred to
as the internal oligonucleotide) that was 5' end-labeled with T4
kinase.
TheDNA encoding theCOON-terminal portionof theenve-
lope protein (beginning at codon453) and aportion ofthe3' open
reading frame (a total of 1,344 bp) was cloned from variant 10E
using the PCR. DNA was amplified using the oligonucleo-
tides5'-dGCTGGAATTCACAAGAGATGGTGGTAATAA and5'-
dTTGGTACCTGTGATTGCTCCATGT The former oligonucle-
otide is at the 5' end of the amplified sequence and incorporates
an EcoRI site, thelatter oligonucleotidecontains a KpnI site.DNA
was amplified using Taq polymerise, and the reagents were sup-
pliedwith theGeneAmpkit (Perkin Elmer Cetus, Norwalk, CT).
DNA was subjectedto 40 cycles of 1 min at 94°C, 1 minat 42°C,
and2min at 72°C.Theamplificationof thecorrect target sequence
wasconfirmed by Southern DNA hybridization with theinternal
oligonucleotide. Amplified DNA was run on a 0.7% low melt
agarose gel, excised, and extracted with phenol. The DNA was
further purified on an Elutip-D (Schleicher & Scheull, Inc., Keene,
NH) before being ligated into pTZ-18R (Pharmacia Fine Chem-
icals), which had been cut with EcoRl and KpnI. Clones were
screened by colony hybridization using the internal oligonucleo-
tide. Plasmid preparations were made from thepositive clones, and
the presence ofHIV sequences was confirmed by restriction map-
ping. Four independent clones (designated 10E-2, 10E-3, 10E-6,
and10E-7) were obtained containing thePCRamplified sequences
from variant cell line 10E. Sequence analysis was performed on
double-stranded DNA using Sequenase (United States Biochem-
ical Corp., Cleveland, OH) and the following oligonucleotides:
M13 -20 primer 5'-dGTAAAACGACGGCCAGT; M13 reverse
5'-dAACAGCTATGACCATG; and the HIV sequences 5'-dCT
GTAGGAGATTCCACC, 5'-dTCACAGTCTGGGGCATCA, 5'-
TGGTGAGTATCCCTGCCT, 5'-dGCCTTGGAATGCTAGTTG,
5'-dTCAGCTCGTCPCATTCTT, 5'-dTTCACTAATCGAATGGA,
5'-dCCAGGTCGTGTGATTCC, and 5'-dGCCAAGGATCCG-
TCAC.
The mutation found in the envelope gene was reconstructed in
theinfectious HIVcloneHXB-2, whichcontains theHIVsequence
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introduced into the pSVgpt expression vector (6). The 2,700-bp
Sall-BamHI fragment of HXB-2 was subcloned into pGEM-4
(Promega Biotec, Madison, WI) and designated HXB-SB. The
PvuII-HindlII fragment from this subclone was ligated to the
HindIII-BamHIfragment from thevariant clone10E-2 andcloned
into pSP-72 (Promega Biotec). The PvuII-BamHI fragment was
excised, ligated to theSall-PvuII fragment derived from HXB-SB,
andinserted into pTZ-18R. This in turn was excised with Sall and
BamHIandligated to the 14KB SalI-BamHI fragment ofHXB-2.
In this way, the finalconstruct derives entirely from HXB-2, with
theexceptionof aHindIII-BamHI fragment (bases 8140-8474) that
encodes theportion ofthe envelope gene containing the mutation
derived from the 10E variant. The presence of this mutation in
the new constructions was confirmed by sequence analysis. Two
different constructs, designated 7.4 and 7.5, were made. Plasmid
DNA from this construction wastransfected into COS-1cellsusing
calciumphosphate. DNA(10wg) wassuspendedin 0.2 ml ofHBSS
containing 125 mM CaC12. After 30 min, a light precipitate
formed and the mixture was added to 5 x 101 COS-1 cells in 35-
mm tissue culture plates. 2-4 d later, cells were stained by im-
munoperoxidase with anti-HIV sera andwere assayed fortheproduc-
tion of infectious HIV by focal immunoassay.
TreatmentofBulkPopulations with 907-RAC.
￿
H9/HTLV
IIIB cells were incubated in the presence of 907-RAC at 2.5
ug/ml (low dose) or 10 /cg/ml (high dose) for 10 d. There
was an initialperiodofcell death, followedby theoutgrowth
of a subpopulation of cells. The survivingcellswere washed
and tested for their response to treatment with 907-RAC
and for their ability to form infectious centers. The response
of the cells to 907-RAC was measured by the uptake of
35S-methionine into cellular proteins in the presence of the
immunotoxin (Table 1). H9/HTLVIIIB were exquisitely sen-
sitive to theaction of the immunotoxin, with >90% inhibi-
tion of protein synthesis. No inhibition wasseen in thepres-
ence of antibody 907 alone. Variant cells treated with a high
dose of the immunotoxin were able to resist the action of
907-RAC, whilecells treated in thepresence of a lower dose
were stillpartially susceptible to theaction oftheimmunotoxin
(ti50% inhibition). The ability of the treated cells to pro-
duce infectious HIV was measured using the focal immuno-
Cells were cultured for 72 h in the presence of the indicated reagent. During the final 16 h, 35S-Met was present. Results are the cpm of
35S-Met incorporated into cellular protein. The mean ± SEM of triplicate samples is shown.
Table 1. Selection
Cell
of907-RAC-Resistant Variants
Media
in Bulk Populations
907 alone
(10 ug/ml)
907-RAC
(10 p.g/ml)
907-RAC
(2.5 Rg/ml)
H9/HTLV-IIIB 66,629 ± 1.758 70,543 ± 11,392 4,024 ± 82 5,043 ± 90
High-dose variants 42,420 t 1,629 35,791 ± 1,122 38,572 ± 922 43,013 ± 2,361
Low-dose variants 52,788 t 1,366 47,377 ± 516 23,207 ± 9,234 17,764 ± 1,411Cells were cultured for 72 h in the presence of the indicated reagent. During the final 16 h, 35S-Met incorporated into cellular protein. The
mean ± SEM of triplicate samples is shown.
assay. Surprisingly, the cells treated with the immunotoxin
produced extremely low levels ofinfectiousvirus (0.5 ± 0.06%
ICs) when compared with the parental H9/HTLVIIB cells
(64.7 ± 4 .3% ICs). These data suggest that the process
allowing for escape from immunotoxin action also renders
the cells noninfectious. To explore the molecular mechanisms
involved, 907-RAC-resistant clones were derived.
Cloning of H9/HTLVIIIB Cells in the Presence of 907-
RAC. Cells were cloned in 96-well tissue culture plates at
a concentration of 10-1,000cellsper well. 907-RAC was added
to 2.5 Ftg/ml, and fresh immunotoxin was added every 4 d.
Colonies became visible at 12-16 d of culture. Colonies arose
at a frequency of between 0.1 and 1.0%. Seven cloned lines
were chosen for further analysis. Clonality was established
by frequency analysis (<10% of wells positive). As the data
given below will demonstrate, these clones fell into two
groups. Members ofeach group appeared to be identical. These
groups of immunotoxin-resistant variants have been desig-
nated the E series (3E, 7E, 8E, 10E, and 11E) and the F series
(4F and 10F).
Sensitivity ofVariant Clones to 907-RAC.
￿
Variant cells were
tested for their sensitivity to immunotoxin-mediated suppres-
sion of protein synthesis. Uptake of 35S-methionine into cel-
lularprotein was measured in cells incubated in the presence
of media, immunotoxin, or antibody 907 alone (Table 2).
H9/HTLVIIIB cells were inhibited >90% by the im-
munotoxin at both doses tested. The three E series variants
tested were each partially inhibited in a dose-dependent manner
by 907-RAC. Variant 4F was not inhibited at all.
Expression ofHIV Antigens on Variant Cells.
￿
The expres-
sion of HIV envelope antigens on the surface of living cells
was studied by flow cytometry. Cells were stained with anti-
body 907 or an irrelevant isotype-matched monoclonal T7,
followed by fluorescein-conjugated goat anti-mouse Ig. The
results (Fig. 1) demonstrate that both ofthe E variants tested
had markedly reduced levels of envelope antigen expression
on their cell surface when compared with the parental cell
line H9/HTLVIIIB. Variant 4F had no detectable envelope
antigen on its surface. Similar results were obtained with an-
tibodies detecting other epitopes on the envelope protein (not
shown). Viral antigens within the cell were studied by im-
munoperoxidase staining on methanol-fixed cells. HIV an-
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tigens were detected in fixed cells with pooled human anti-
HIV antisera and peroxidase-conjugated goat anti-human Ig
(Fig. 2). Visual inspection indicates that the E variants con-
tained at least as much viralantigen internal to the cell mem-
brane as the parental H9/HTLVIIIB cells, possibly more. No
viralantigens were seen in uninfected H9 cells and the F vari-
ants. These data suggest that the E variants produce HIV
proteins, but that these proteins are poorly expressed on the
cell surface when compared with the parental H9/HTLV
IIIB cells. There is no evidence that the F variants produce
any viral proteins.
Production ofReverse Transcriptase by Variant Cells.
￿
Reverse
transcriptase activity secreted into cell supernatants by the
variant cells was measured (Fig. 3). The E variants produced
as much (or more) reverse transcriptase as H9/HTLVIIIB.
The F variants produced no detectable reverse transcriptase
activity. These data are consistent with the interpretation of
S
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Figure 1.
￿
Flow cytometric analysis of gp120 on the surface of
variant cells. The parental cell line H9/HTLVIIIB and three immuno-
toxin-resistant variant cell lines were stained with anti-gp120 antibody
907 or control antibody T7 followed by fluorescein-conjugated goat
anti-mouse Ig. Cells were fixed and analyzed by flow cytometry.
When compared with the parental cells, both the E variants had
greatly decreased levels of antibody binding. The F variant had no
cell surface gp120 expression.
Table 2. Susceptibility of Variant Clones to 907-RAC
907 alone 907-RAC 907-RAC
Cell Media (10 Jig/ml) (10 hg/ml) (2.5 lAg/ml)
H9/HTLV-IIIB 24,502 ± 1,336 25,721 ± 388 1,654 ± 115 2,561 ± 65
3E 44,679 ± 2,338 42,709 ± 1,426 29.949 ± 522 35,045 ± 853
11E 51,308 ± 3,011 48,906 ± 765 35,866 ± 227 44,378 ± 1,029
10E 53,656 ± 1,758 48,999 ± 414 24,629 ± 210 34,791 ± 1,647
4F 34,026 ± 1,055 34,072 ± 583 38,589 ± 536 38,039 ± 2,484Fig. 2 that theEvariants produce normal levels of viral pro-
teins, while the F variants fail to produce any.
p24Antigen Levels in Variant Cells.
￿
The intracellular con-
centration of theHIVp24core antigenwas measured in Triton
X-100-lysed H9, H9/HTLVIIIB, 10E, and4F cells . The p24
levels were measured in an antigen capture assay. Serial dilu-
tions of lysed cells were compared with a standard curve .
H9/HTLVIIIB contained 0.188 ± 0.004 pg/cell of p24 an-
tigen; 10E contained 0.153 ± 0.011 pg/cell. Both H9 and
4F cells contained <10 -5 pg/cell (that is, 105 cells produced
a signal equal to background, with adetectable signal at 1.56
pg/well) . The exact numbers for the antigen concentration
per cell maynot be strictly accurate, since this assay was de-
signed and tested on supernatant fluids . However, the data
clearly indicate that there areroughlyequivalent antigen con-
centrations in H9/HTLVIIIB and 10E cells, while there is
no antigen detectable in the 4F variants.
SDS-PAGE Analysis ofSecretedHIVEnvelope Proteins.
￿
HIV
envelope proteins were assayed in the supernatants of variant
cells by radioimmunoprecipitation and SDS-PAGE analysis
Figure 3 .
￿
Supernatant reverse transcriptase activity of variant cells.
Supernatants from parental and variant cells were examined for the
presence of reverse transcriptase activity. The parental H9/HTLVIIIB
and E variant cells produced equivalent amounts of reverse transcrip-
tase, none was produced by F variant cells .
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Figure 2 .
￿
Immunoperoxidase
staining of variant cells. Unin-
fected H9, H9/HTLV-IIIB, and
variant cells were fixed in
methanol and stained with
pooled human anti-HIV an-
tisera followed by horseradish
peroxidase- conjugated goat
anti-human Ig . Antibody was
localized using the chromo-
genic substrate aminoethyl car-
bazole. The results demonstrate
that viral antigens were de-
tected to an equal degree in
the H9/HTLV-IIIB and E
variant cells. No HIV antigens
were seen in H9 or the F
variants.
(Fig . 4) . Theleft-hand lane contains the lysate ofCOS-1 cells
infected with the infectious HIV clone HXB-2, and serves
as a marker for the normal length of the envelope proteins
gp120 andgp160 . H9/HTLVIIIB cells only secreted thema-
ture gp120. The E variants secreted gp120, but they also
released an altered form of the envelope of -145M This
altered protein is most likely a truncated form of gp160 that
has not been properly processed into the mature envelope
protein gp120 . This antiserum did not precipitate gp41 or
gagproteins from cell supernatants . TheFvariants produced
no detectable viral protein .
Figure 4.
￿
Release of HIV
envelope proteins into cell su-
pernatants . A radioimmunopre-
cipitation was performed using
antienvelope antibody and pro-
tein A to precipitate envelope
proteins secreted by the pa-
rental and variant cell lines . A
lysate of COS-1 cells trans-
fected with the infectious clone
HXB-2 was included for com-
parison purposes . The parental
cell secreted only gp120 . The E
variants produced gp120 and a
145-kD form of the envelope
protein. Variant 4F produced
no envelope proteins .Ultramicroscopic Analyses of Variant Cells.
￿
Thin section
profiles ofH9/HTLVIIIB and the variant cells were studied
by electron microscopy. Fig . 5 shows the results seen with
variant 10E . Although there were a few viral particles demon-
strating the typical budding normally seen with lentiviruses
(Fig. 5 A1), the majority of viral particles were contained
within intracellular vesicles (Fig. 5A) . In contrast, H9/HTLV
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Figure 5 .
￿
Ultrastructural anal-
ysis of the 10E variant cells. Thin
section profiles of variant 10E
were examined by electron micros-
copy. (A) A vacuole containing
viral particles, not typically seen in
T cells infected with HIV A bud-
ding virus is seen in the insert of
A and at higher magnification in
AI . (B) A surface-budding particle
exhibiting the early pre-condensing
profile ofHIV (C) Extracellular
viral particles. Large arrows denote
typical morphotypes of HIV,
while small arrows denote aber-
rantly formed particles . Bar mark-
ers : (A) 1,000 nm; (AI) 100 nm ;
(B) 100 nm ; (C) 200 urn .
IIIB cells had large numbers of viruses budding from the
plasma membrane (not shown) . This is consistent with and
partially explains the data obtained by flow cytometry. Ex-
tracellular viral particles demonstrated typical morphology
as well as aberrant forms in both the variant (Fig . 5, A1,
B, and C) and HTLVIIIB (not shown) . No viral particles
were seen in the F variants .
Immunodeficiency Virus VariantsThe indicated cell lines were incubated with adherent HT4-6C cells
for 24 h and washed off. 72 h later, the HT4-6C cells were fixed
and stained with anti-HIV anti-serum and a peroxidase-conjugated
secondary antibody . The results are presented as the percentage of
input cells forming viral foci .
Inability ofE Variants to Infect CD4+ Cell Lines.
￿
The E
variants secrete viral particles containing an aberrant enve-
lope protein . To determine ifthis alteration changes the func-
tional capacity of the virus produced,'we measured the ability
of these viruses to infect CD4+ cell lines (Tables 3 and 4) .
Table 3 shows infection ofHT4-6C cells by H9/HTLVIIIB
and the five E variants. The results, shown as the percent-
age of input cells forming viral foci, demonstrate the ina-
bility of the E variants to cause a productive infection . Infec-
tion of T cells was also tested (Table 4) . H9/HTLVIIIB or
10E cells were irradiated (1,200 rad) and mixed in the indi-
cated ratio with the target cells. 5 d later, cells were fixed
and stained with anti-HIV antiserum, and the percentage of
cells expressing viral antigens was determined . H9/HTLV
IIIB was able to establish infection in both the target cell
lines ; 10E did not . These data demonstrate that the virus pro-
duced by the E variants is not infectious as assayed on these
cell systems.
Table 4.
￿
Ability of Variant Cells to Infect CD4+ T Cell Lines
Irradiated infecting cells were mixed in the indicated ratio with
uninfected target cells. Data show the percent target cells staining
with anti-HIV antiserum 5 d after coculture with the infecting cells .
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Figure 6 .
￿
CD4 binding by
proteins produced by parental
and variant cells . Proteins
secreted by cells were analyzed
for CD4 binding activity by
radioimmunoprecipitation with
immobilized CD4 . H9/HTLV
IIIB cells produced only a
single protein, gp120, that
bound to CD4 . This binding
could be blocked with soluble
CD4 . Both gp120 and the al-
tered envelope protein (gp145)
bound to CD4 in the E variant
cells . Variant 4F produced no
CD4 binding proteins . A lysate
of COS-1 cells transfected with
HXB-2 serves a standard for
comparison of molecular sizes .
CD4 Binding by Variant HIVs.
￿
One possible explanation
for the inability of the variant HIVs to infect CD4+ cells
is that the altered envelope cannot bind to CD4. To test this,
radioimmunoprecipitation was performed usingCD4 immobi-
lized on sepharose to precipitate the labeled proteins in cell
supernatants (Fig. 6) . The HXB-2 lysate serves as a size stan-
dard . H9/HTLVIIIB cells exported one C134-binding pro-
tein,' gp120 . This binding was blocked by the presence of
soluble CD4 . Both secreted forms of the envelope protein
ofthe E variants (gp120 and truncated gp160) bound to CD4 .
The failure of the E variants to infect CD4' cells is not due
to the inability of the altered envelope to bind to CD4 .
Analysis ofEnvelope Genes in E Variant Cell Lines.
￿
The
production of a normal gp120 and a shortened gp16Q led us
to search in the portion of the envelope gene encoding gp41
for-a mutation . Using the PCR, DNA from codon 453 of
the envelope gene and extending 1,344 by downstream (into
the 3' open reading frame) was amplified . Southern hybrid-
ization analysis with the internal oligonucleotide demonstrated
that there was no major deletion within this portion ofDNA
(Fig. 7) . The hybridizing fragment was of equal length in
the H9/HTLVIIIB and the 10E variant cells. Amplification
ofDNA from uninfected H9 cells produced no signal . Fine
structural analysis was performed by cloning'and sequencing
the PCR-amplified fragment . Amplified DNA of the cor-
rect length was excised from an agarose gel, cut with KpnI
and EcoRI (restriction sites were built into the amplification
primers), and cloned into pTZ-18R . The DNA sequence of
the amplified fragment showed the presence of a single base
deletion after codon 686 of the envelope protein, resulting
in three translational stop codons immediately after the dele-
tion (Fig. 8) . The predicted length of the protein derived
from this mutation is the same as the observed length of the
altered envelope protein (145 kD) . The same mutation was
found in four independently derived clones, ruling out the
possibility that the observed deletion was an artifact ofPCR
amplification . In the 1,344 by that were sequenced, an addi-
tional four single-base substitutions were found, resulting
in two amino acid differences : gly to glu in codon 464, and
val to leu in 673 .
Infecting cell A3 .01
Target cell
H9
None 0 0
H9/HTLV-IIIB
1 :100 0 50
1 :10 23 44 (many dead)
10E
1 :100 0 0
1 :10 0 0
Table 3. Ability
Cell
of HT4-6C Cells to Infect CD4+ HeLa Cells
Percent ICs
H9/HTLV-IIIB 68.5
3E <0 .01
11E <0.01
10E <0.01
8E <0.01
7E <0.01Figure 7.
￿
Southern blot anal-
ysis of amplified envelope gene .
DNA from uninfected H9 cells,
H9/HTLVTI>$ and variant 10-E
cells was amplified using the
PCR with primers that flank
the COOH-terminal portion
of the envelope gene. The
amplified DNA was sized on a
0.7% agarose gel, blotted onto
nitrocellulose, and hybridized
against the internal oligonucle-
otide. The data demonstrate
that the shortened envelope
protein was not due to a dele-
tion within the proviral DNA .
Demonstration that the Mutation Detected in the E Variants
Renders HIVNon-infectious . To test whether the single-base
deletion detected in the envelope gene renders the virus nonin-
fectious, the mutation was reconstructed in the infectiousHIV
clone HXB-2 . Sequences derived from the envelope gene of
variant 10E (corresponding to by 8140-8474 ofHXB-2) were
inserted in place ofthe corresponding HXB-2 sequences. The
variant HXB-2 viruses were transfected intoCOS-1 cells with
calcium phosphate . The efficacy of transfection was measured
by immunoperoxidase staining of the transfected cells . The
infectivity of the HIV was measured by cocultivation of the
transfected cells with theHIVpermissive cell lineA3.01. The
infection ofA3.01 was assayed using the focal immunoassay
(Table 5) . Five simultaneous transfections were performed using
plasmid DNA containing parental HXB-2, two different
variant HXB-2s (designated 7.4 and 7.5), the gene transfer
vector pSVneo (containing noHIV sequences), and a mock
transfection with noDNA. Immunoperoxidase staining of
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the transfected COS-1 cells was seen only withHXB-2, 7.4,
and 7.5 . Only rare cells (<1 in 10'x) contained HIV antigens
2-3 d after the transfection, with two to three times as many
cells staining inHXB-2 transfected wells than in wells receiving
7.4 or 7.5. No infection was produced in A3.01 cells cocul-
tured with 7.4- and 7.5-transfected COS-1 cells, while a sub-
stantial infection was established in A3.01s cocultured with
HXB-2-transfected cells. We have repeated this experiment,
this time transfecting by electroporation . In this second ex-
periment, HXB-2, 7.4, and 7.5 produced equal numbers of
transfectants staining for HIV antigens by immunoperoxi-
dase. Once again, no infectious virus was made by 7.4 and
7.5 transfectants, whileHXB-2 transfectants were able to in-
fect A3.01 cells. Thus, the envelope mutation of variant 10E
renders HXB-2 noninfectious .
F Variants Lack CD4and Cannot be Infected with HIV .
￿
By
all methods of detection, the F variant cells do not express
any viral proteins and appear to be uninfected . Yet, they are
derived from cells permissive forHIV infection and have ex-
isted within a milieu where they had ample opportunity to
be infected . To demonstrate that these cells are indeed resis-
tant to infection with HIV, the variant cell lines 4F and 10F
were incubated withtwo strains of HIV, and then tested for
evidence of infection using the focal immunoassay (Table 6) .
No sustained infection could be produced . The extremely
low level of infectious centers seen with NL4-3 is most likely
due to carry-over virus nonspecifically adhering to the 4F cells,
since at subsequent time points, there were no ICs (data not
shown) . To explore the mechanism for the resistance of the
F variants to infection, we examined the cell surface expres-
sion ofCD4 on these cells (Fig. 9) . Uninfected H9 cells ex-
pressed moderate levels of CD4 . Consistent with previous
observations (11-13), H9/HTLVIIIB cells did not express
Figure 8 .
￿
Sequence of mutation
causing the truncation of the enve-
lope gene in the E variants . A
reproduces the sequencing gel per-
formed on the antisense strand of
DNA. The position of the deletion
is marked . The sequences sur-
rounding the mutation are shown
in B. The RNA sequence of
HTLVIIIB and its translation are
given at the top, and the DNA se-
quence of the mutant provirus and
its translation are given below. The
site of the deletion is marked . Iden-
tical sequences were detected in four
distinct clones derived from the
amplified 10E DNA. (C) A stick
figure of gp160 showing the region
sequenced, the site of the deletion,
and the major structural characteris-
tics : signal peptide, gp120, gp41,
and the transmernbrane portion of
gp41. Numbers indicate amino acid
residues.COS-1 cells were transfected with the indicatedDNA. 2 or 3 d
after transfection, the COS-1 cell monolayers were cocultured with
A3.01 cells for 24 h. The A3.01 cells were removed and tested for
HIV infection with the focal immunoassay either immediately or
after 4 additional days in culture . The data are presented as the
number of infectious centers per 105 input cells .
CD4. Variant 4F also failed to express CD4, thus accounting
for their inability to become infected .
F Variant Cells Contain ProviralDNA that Cannot be Induced
from Latency . Using the SouthernDNA hybridization tech-
nique, we examined DNA of variant cell line 10F and the
parental H9/HTLVIIIB for the presence of proviral DNA
(Fig . 10) . HindIII-digested DNA was blotted against radio-
labeled HXB-2 . Equivalent amounts ofDNA were loaded
in each lane. Although there was a less intense signal in the
10F variants and there were differences in the relative inten-
sity of the different bands, all of the restriction fragments
present in H9/HTLVIIIB were also present in 10F, although
it is possible that the broad band at 7.5 kb inH9/HTLVIIIB
is a doublet . Thus, the F variants were infected with HTLV
Table 6 .
￿
Infection ofF Variants
Percent ICs
HIV strain
￿
Cell
￿
4 d
￿
7 d
None H9 <0.01 <0.01
4F <0.01 <0.01
10F <0.01
￿
0.01
NL4-3
￿
H9
￿
2.5 ± 0.52
4F 0.06
1OF <0.01
26.05 ± 11 .20
0.03
<0.01
NY5
￿
H9
￿
0.81 t 0.09
￿
3 .27 ± 1.10
4F <0.01 <0.01
1OF <0.01 <0.01
Cells were incubated with cell supernatants containing the indicated
strains of HIV and 8 hg/ml of polybrene . 4 and 7 d after infection,
cells were treated for HIV infection using the focal immunoassay .
The results are presented as the percentage of input cells forming
viral foci .
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H9
T7
OKT40
H9/HTLV-111B
T7
OKT48
Variant 4F
T7
OKT4s
Figure 9 .
￿
Cell surface expression
ofCD4 on variant 4F. Uninfected
H9, H9/HTLVIIIB, and variant 4F
cells were stained with the anti-
CD4 antibody OKT4a or the con-
trol antibody T7, and then with
fluoresceinated goat anti-mouse Ig.
Cells were analyzed by flow cytom-
etry . No CD4 was detectable on
H9/HTLVIIIB or variant 4F.
Figure 10 .
￿
Presence of HIV genome
in variant IOF. DNA from H9/HTLV
IIIB or 1OF cells was digested with the
restriction enzyme HindIII, sized on a
0.7% agarose gel, and blotted onto
nitrocellulose. TheDNA was hybrid-
ized to radiolabeled HXB-2. Although
there are differences in the intensity of
hybridization, the presence in 10F
DNA of bands corresponding to each
internal band in H9/HTLVIIIB can be
seen .
Table 5. Infection ofA3.01 Cells by Transfectants
DNA transfected
A3 .01 cells 7.4 7.5 HXB pSVneo 0
Day 2 fresh 0 0 30 0 0
Day 2 cultured 0 0 1,660 0 0
Day 3 fresh 0 0 12 0 0
Day 3 cultured 0 0 368 0 0IIIB at some point in time. The virus has subsequently ei-
ther become latent or suffered a debilitating mutation that
prevents viral expression. To determine if the virus is in a
state of latency, 4F and 10F cells were incubated with agents
that areknown to activate latentHIV (14, 15) . Neither phorbol
esters nor various mixtures of ILs and cytokines were able
to induce HIV expression by F variant cells, as measured by
the focal immunoassay.
Discussion
The resistance of microorganisms to antimicrobial therapy
has emerged as a major problem in the treatment of infec-
tious diseases. The phenomenon is well established in bac-
terial populations and has also begun to emerge as a serious
issue with viruses ; acyclovir resistant herpes viruses have been
reported (16) . Variation ofHIV is well established, and most
likely results from an error-prone reverse transcriptase (17,
18) . This diversity results in antigenic variation (19), as well
as the emergence of HIV with altered biological properties
(20-22) . Because of the extreme variability of HIV, variants
may arise that might then be amplified under the selective
pressure of antiviral therapy. Azidothymidine (AZT)-resistant
HIV has'been reported, and mutations in the reverse tran-
scriptase gene are thought to be responsible for this resis-
tance (23, 24) . In the case of immunologically targeted anti-
HIV agents, changes in antigenic structureswould allow for
escape variants . A single point mutation in the envelope gene
can generate HIV resistant to neutralization by immune an-
tisera (25) . In this report, we have used an antibody-targeted
immunotoxin to generate HIV variants that escapeimmuno-
logic destruction . The antibody is directed against the hyper-
variable immunodominant PB-1 loop of the HIV envelope,
gp120 . Because of the variability of the target structure, we
expected that escape variants would have alterations in the
epitope recognized by the antibody. Instead, we found that
alterations elsewhere in the virus affect the levels of envelope
protein expressed on the surface of the HIV-infected cells,
and were responsible for immunotoxin resistance .
We have identified two sets of variant cells arising from
the immunotoxin-treated HIV-infected cell line . Because the
cells within each set appear to be identical, and the first ex-
posure of the cells to the immunotoxin was when they were
cloned in its presence, it is likely that the variation preceded
the selection process. The F variants escape the action of the
immunotoxin because the virus is not expressed in these cells .
Without viral envelope expression on the surface of the F
variants, the immunotoxin does not bind, and the cells sur-
vive. The mechanism of HIV latency in the F variants has
not been established . The E variants contain a single base
deletion after codon 686 of the envelope gene that results
in premature termination of translation and the production
of a truncated gp160 . This altered envelope protein is not
completely processed, which in turn results in abnormal viral
secretion and a marked decrease in the expression ofenvelope
on the surface of the infected cell . The mutation in the enve-
lope gene also renders the virus noninfectious, which is con-
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sistent with previously reported studies using site-directed
mutagenesis (26) .
Our results with the E series variants are reminiscent of
findings seen with Friend murine leukemia virus. Kabat et
al . (27) used antibody and complement to select for Friend
virus mutants that express their envelope genes aberrantly
and that accumulate unusual intracellular forms of the enve-
lope glycoproteins. Pinter et al. (28) used inhibitors ofoligosac-
charide processing to study the processing ofthe Friend enve-
lope protein . Tunicamycin completely inhibited glycosylation
of the envelope protein, which led to a failure of proteolytic
cleavage . Deoxynojirimycin, an inhibitor of cellular glycosi-
dases involved in the final processing of the carbohydrate
moiety, resulted in decreased levels of cell surface envelope
protein, and an accumulation of virus within intracellular
vesicles. Electron micrographs of deoxynojirimycin-treated
cells show the same findings as Fig . 5 in this report (28) .
The emergence of immunotoxin-resistant variants has been
studied in tumor cells (2) . B cell tumors were treated with
an antiidiotypic antibody coupled to saporin . Immunotoxin-
resistant variants fell into two classes . In the first, cell surface
Ig was absent, while in the second, mutations in the V re-
gion rendered the Ig nonreactive with the antiidiotypic anti-
body. The variants that we have detected in this study most
closely resemble the Ig-negative B cell tumor variants, al-
though in the case of our E variants, the molecule bearing
the target structure is present, but in decreased quantity . Re-
sistance of the E variants to immunotoxin action is relative ;
the cells are partially susceptible to high doses of immunotoxin .
This is an excellent example o£ correlation between cell sur-
face antigen density and the vulnerability of the cell to an
immunotoxin binding the antigen. This finding has impli-
cations for the treatment of neoplastic disease with im-
munotoxins .
The failure of the F variants to express CD4 is surprising .
The disappearance of cell surface CD4 in HIVinfected cells
is well documented . However, this phenomenon is thought
to be due to intracellular binding ofCD4 by the viral enve-
lope (11-13) . In the case of the F variants, we were unable
to find evidence that any viral proteins were produced, sug-
gesting that a different mechanism is responsible for their
failure to express CD4 . Although these cells have been in-
fected with HIV, we have no data to suggest that this infec-
tion is responsible for the failure of the F variants to express
CD4 . An equally likely possibility is that there has been a
mutation in the CD4 gene that prevents it from being ex-
pressed . Sincewe have shown that these CD4- cells cannot
be reinfected with HIV, treatment of the tissue culture cell
line with immunotoxin would select for these CD4- ,
HIV - variants . Whatever the reason for the failure of the
F variants to express CD4, this failure has resulted in the
inability of the F variants to become infected by HIV a second
time. The configuration of the proviralDNA in the genome
of the F variant cells confirms that only a single infection
has occurred .
Naturally arising mutations that result in a truncated gp160
have not been previously reported for HIV. However, suchmutations have been seen in the simian immunodeficiency
virus (SIV) (29). The most commonly seen SIV mutation
results in a truncation of approximately the same size that
we have reported. The SIV truncation results from base sub-
stitutions rather than the single base deletion that we have
seen. The truncated SIV are infectious and appear to result
from the passage of SIV through human cells. When SIV
with a full-length envelope is passaged in human cells, trun-
cated variants arise; when truncated SIV is passaged through
macaques or macaque cells, full-length variants arise. The rela-
tionship between these mutations in SIV and the mutation
that we have observed is unclear.
The development of vaccines to prevent HIV infection has
been problematic (30, 31). According to conventional wisdom,
"whole virus vaccines do not represent a practical avenue for
a vaccine against AIDS because of the possibility of infec-
tious particles" (31). Thus, reductionist approaches have been
taken, including the use ofrecombinant envelope protein (32),
synthetic polypeptides (33, 34), and the introduction o£ var-
ious HIV epitopes into genetically engineeredvaccine vectors
(35, 36). Although most of these maneuvers can elicit neu-
tralizing antibodies, protection against viralchallenge has not
been demonstrated. In fact, immunization with recombinant
gp120, a more complete immunogen than some of the other
proposed vaccines, failed to protect chimpanzees from HIV
challenge in the presence of a strong anti-HIV neutralizing
antibody and T cell response (32). In contrast, studies utilizing
inactivated whole virus preparations have demonstrated pro-
tective efficacy in SIV infection of macaques (37, 38). Per-
haps it may be worth reconsidering the use of whole virus
HIV vaccines. The E variants described in this study could
serve as models for viruses that are first rendered noninfec-
tious by genetic modifications and then by chemical or me-
chanical disruption. The studies described here demonstrate
that such genetically altered viruses have morphologic and
antigenic characteristics not too different than the native HIV
During several months of passage of the E variant cells, we
have not had any reversion to infectious HIV, although a rig-
orous selection for revertants was not applied. Safety could
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be increased by engineering additional mutations. We are cur-
rently evaluating the immunogenicity of the virus produced
by the E variant cells.
The studies presented in this communication address the
general issueofevasion of immunologic surveillance as a mech-
anism of viral persistence. The role of antibody in this
phenomenon is well studied in a number of different viral
systems (39). The best known example is the antigenic shift
and drift that allows the influenza virus to persist in popula-
tions. An example ofescape from immune surveillance in an
individual animal occurs with the lentivirus that causes equine
infectiousanemia. Recurrent episodes ofclinical illness correlate
with the emergence of viral variants resistant to neutraliza-
tion with serum antibodies. Analysis of these variants shows
alteration of the envelope glycoproteins (40). In addition to
selecting for variant viruses with altered antigens, antibodies
may induce changes in the cells that harbor viruses, allowing
the virus to persist in these cells. Noncytotoxic antibodies
have been shown to cap and remove measles virus antigens
from the surface of infected cells, allowing these cells to es-
cape destruction by other immunologic effector mechanisms
(41). Similarly, antibodies lacking neutralizing and cytotoxic
activity may serve as blocking antibodies, preventing recog-
nition and removal of the virus by the immune system (39).
The role of antibody in the progression of HIV infection
from acute infection through latency to AIDS is the focus
of intense investigation. Evidence exists showing that some
specific antibody response is beneficial in inhibiting the dis-
ease process (42), and that loss of anti-p24 and anti-gp120
antibodies is associated with progression to outright AIDS
(43). Administration of anti-HIV antibodies to AIDS patients
appears to have a beneficial effect (44). On the other hand,
there is concern that serum antibody may enhance the ability
of HIV to infect cells via an Fc receptor-dependent mecha-
nism (45). Understanding the relationship between protec-
tive antibody responses, antibodies that enhance infection,
and the effects of antibody on HIV persistence and antigenic
variation will allow us to design more effective vaccines and
antibody therapies for the prevention and treatment ofAIDS.
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